Wobble Base®
BioResearch

HIV-1 Drug resistance genotyping [Conventional PCR and Sanger DNA Sequencing]

OUR CERTIFICATIONS

Our certifications

✓ ISO 13486:2016 certified

✓ ISO 9001: 2015 certified

✓ DPIIT (Govt. of India) certified

✓ Institutional Biosafety Committee (DBT)

✓ MSME Registered

✓ Trademark Registered with Trade Mark, Registry, Govt. of India

CONTACT

PHONE:
+91-6353339602

WEBSITE:
Wobblebase.in

EMAIL:
support@wobblebase.in

GRANTS/AWARDS

- ✓ Biotechnology Ignition Grant Award-2013
- ✓ Grand Challenge-TB Control - Bill and Melinda Gates Foundation | USAID | BIRAC, Govt. of India Phase-1 Grant -2015;
- ✓ Grand Challenge-TB Control - Bill and Melinda Gates Foundation | USAID | BIRAC, Govt. of India Phase 2 Grant-2017
- ✓ Grand Challenge Explorations- Bill and Melinda Gates Foundation | USAID | BIRAC, Govt. of India Grant-2017
- ✓ DBS-NUS Social Venture Challenge Asia 2017 Finalist.
- ✓ BIRAC (Dept. of Biotechnology) Pre- Accelerator MedTech Challenge Grant-2021
- ✓ Fastest Growing Indian Company Award (2019) – International Achievers Conference, Bangkok
- ✓ Small Business Innovation Research Initiative (SBIRI) (2013) – Dept. of Science and Tech., Govt. of India.

INTRODUCTION

- WobbleBase HIV-1 Drug resistance genotyping kit is used to determine whether a patient with HIV has a mutated form of the virus that does not respond to antiretroviral therapy (ART).
- With the help of PCR amplification, our kit swiftly identifies even the smallest traces of HIV-1 genetic material, enabling precise analysis. Coupled with DNA sequencing, it provides comprehensive insights into the genetic makeup of the virus, pinpointing specific mutations associated with drug resistance.
- Whether for clinical diagnostics or research purposes, our kit delivers rapid and reliable results, guiding personalized treatment strategies and advancing HIV management.
- This kit scans the PR and RT gene of the virus to detect mutations related to drug resistance against Protease, non-nucleoside reverse transcriptase inhibitor & nucleoside reverse transcriptase inhibitor.

KEY FEATURES

- High sensitivity & accuracy.
- Minimize the risk of false negatives and false positives.
- Easy work flow & compatible with various PCR instruments.
- Available in different pack sizes
- Reliable and cost effective.
- Available in different pack sizes
- Reliable and cost effective.

SPECIFICATIONS

Technology	Conventional nested PCR amplification and Sanger DNA Sequencing
Type of Analysis	Qualitative
Target Sequence	Focused detection on consensus drug resistance mutations (DRMs) in the protease and reverse transcriptase (PR/RT) and integrase (IN) regions of the HIV-1 pol gene
Analytical Specificity	Detection of all subtypes in human EDTA Blood, 100 %
Analytical Sensitivity (LoD with probability 95 %)	100% on the samples with HIV-1 viral load 1000 RNA copies/ml.
Diagnostic Specificity	99.6 ± 0.3%
Diagnostic Sensitivity	98.2 ± 0.9%
Controls	Positive control

HIV-1 Drug resistance genotyping [Conventional PCR and Sanger DNA Sequencing]

✓ TATA Health Fund (Phase 1 - Biosafety) – 2024

Validated Specimen	HIV-1 from Human EDTA plasma
Storage	-20 ± 5 °C
Instrument	Compatible with a wide range of conventional PCR devices and ABL DNA capillary electrophoresis sequencing

Your thinking partner in science

CATALOG NUMBER	PRODUCT INFORMATION
HIVDR/WBB/25	HIV-1 Drug resistance genotyping PCR Kit
HIVDR/WBB/100	HIV-1 Drug resistance genotyping PCR Kit